Jubilant Pharmova Ltd.
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 1978-01-01
- Employees
- 5K
- Market Cap
- $1.7B
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: JI-101
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Jubilant Innovation Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT00842335
- Locations
- 🇺🇸
Premiere Oncology of Arizona, Scottsdale, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath